Engineering artificial microbial consortia for personalized gut microbiome modulation and disease treatment

The human gut microbiome is a complex ecosystem that plays a vital role in maintaining health and contributing to the pathogenesis of various diseases. This review proposes a transformative approach that involves engineering artificial microbial consortia—precisely designed communities of microorganisms—for personalized modulation of the gut microbiome and targeted therapeutic interventions. By integrating synthetic biology, systems biology, and advanced culturing techniques, tailored microbial consortia can be developed to perform specific functions within the gut, including the production of therapeutic molecules, modulation of immune responses, and competition against pathogenic bacteria. In vitro and in vivo studies indicate that these engineered consortia can effectively restore microbial balance and enhance host resilience. This personalized approach holds immense potential to revolutionize healthcare by addressing the root causes of diseases such as metabolic disorders, inflammatory conditions, and gastrointestinal infections through precise manipulation of the gut microbiome. Future research should focus on rigorous clinical trials to evaluate the safety, efficacy, and long‐term impacts of these engineered consortia in diverse human populations, paving the way for innovative microbial therapies that promote overall health and well‐being.